Exploring the Potential Reproductive and Hormonal Effects of GLP-1 Medications in Women With PCOS

As glucagon-like peptide-1 receptor agonists continue to gain widespread attention for managing metabolic health and weight, researchers are increasingly examining their broader physiological impacts. A recent scoping review published in the journal Cureus investigates whether these pharmacological treatments extend beyond metabolic regulation to influence gynecologic, hormonal, and reproductive outcomes in females diagnosed with polycystic ovary syndrome, which is also referred to as polyendocrine metabolic ovarian syndrome.

Understanding Polycystic Ovary Syndrome and Current Management

Polycystic ovary syndrome is widely recognized as one of the most prevalent endocrine disorders affecting individuals of reproductive age. The condition is frequently accompanied by metabolic challenges such as insulin resistance, obesity, dyslipidemia, and an elevated long-term risk of developing diabetes. Standard clinical care often centers on lifestyle modifications and weight management for patients with overweight or obesity. However, achieving and sustaining long-term weight reduction through lifestyle changes alone remains notoriously difficult.

To address metabolic dysfunction, clinicians increasingly utilize medications. Glucagon-like peptide-1 receptor agonists are known to improve glycemic control and promote weight loss. Because metabolic health and reproductive function are closely intertwined in patients with polycystic ovary syndrome, investigators sought to map out existing evidence regarding how these therapies might impact menstrual regularity, hyperandrogenism, and fertility.

Overview of the Scoping Review

To evaluate the current state of the science, researchers at Nova Southeastern University in Davie, Florida, conducted a comprehensive database search across multiple platforms, including PubMed, Embase, Web of Science, and the Nursing and Allied Health Premium database. Their objective was to identify studies assessing glucagon-like peptide-1 receptor agonists in females with polycystic ovary syndrome that reported gynecologic or reproductive outcomes.

Out of 1,416 initial records identified, 28 studies ultimately met the inclusion criteria after rigorous screening and full-text analysis. The investigated treatments most commonly involved liraglutide, exenatide, and semaglutide. Because the reviewed studies varied significantly in design, intervention types, outcome measures, and follow-up durations, the authors summarized the findings narratively rather than conducting a quantitative meta-analysis.

Key Findings on Hormonal and Menstrual Outcomes

The scoping review highlighted several notable patterns across the included literature:

• Hyperandrogenism: Biochemical markers of elevated male hormones showed the most consistent improvements. Multiple studies reported significant reductions in total and free testosterone, androstenedione, and the free androgen index, alongside increases in sex hormone-binding globulin. Some reports also noted decreased luteinizing hormone levels.
• Menstrual Function: Menstrual outcomes were assessed across 13 studies. A subset of these trials observed improvements in menstrual frequency, regularity, and bleeding patterns, as well as reductions in amenorrhea, particularly among individuals achieving substantial weight loss. However, other studies found no statistically significant changes in menstrual regularity.
• Fertility and Ovulation: Ovulation rates and fertility markers were examined in nine studies, yielding encouraging yet limited data. Improved ovulation was observed following treatment, especially when therapies were combined with metformin. A small randomized pilot trial involving 28 participants also noted higher pregnancy rates during subsequent in vitro fertilization cycles among women who received preconception treatment with liraglutide combined with metformin compared to metformin alone.

Important Study Limitations

While the findings suggest potential benefits, the authors of the review emphasized several key limitations within the existing literature. The scoping review did not perform a critical appraisal or a formal assessment of the risk of bias and certainty of evidence. Furthermore, the included studies often featured smaller sample sizes, shorter follow-up periods, or evaluated reproductive outcomes merely as secondary endpoints.

Substantial heterogeneity across study designs, patient populations, and intervention regimens also complicates efforts to isolate specific treatment effects. Crucially, because nearly all studies demonstrated concurrent improvements in body mass index, body weight, and insulin sensitivity, researchers cannot yet definitively determine whether the observed reproductive and gynecologic improvements occurred independently of weight loss. Additionally, the review did not evaluate pregnancy safety; established clinical guidelines recommend discontinuing glucagon-like peptide-1 receptor agonists prior to a planned conception due to limited safety data during pregnancy.

Future research requires larger, well-designed randomized controlled trials specifically targeted at reproductive endpoints to clarify the direct mechanisms of these medications and distinguish their hormonal effects from the secondary benefits of weight reduction.